MRTX logo

Mirati Therapeutics (MRTX) Selling, General & Administrative Expenses

Annual SGA

$239.80 M
+$103.12 M+75.45%

December 31, 2022

Summary

Performance

1-Year Change

+75.45%

3-Year Change

+463.26%

5-Year Change

+1682.88%

15-Year Change

+1682.88%

MRTX SGA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

High & Low

All-time High

$239.80 M
MRTX annual SGA is currently at an all-time high

3-Year Low

$136.68 M
MRTX annual SGA is currently +75.45% above its 3-year low

Earnings dates

Last Annual Earnings Report Date

Dec 31, 2022
MRTX previous annual earnings announcement was published on Dec 31, 2022

Next Annual Earnings Report Date

N/A
MRTX next annual earnings announcement has not yet been scheduled

OtherMRTXexpensesmetrics:

Annual Total Expenses

$772.02 M
MRTX annual total expenses is $772.02 million

Annual Operating Expenses

$771.42 M
MRTX annual total operating expenses is $771.42 million

Annual Cost Of Goods Sold

$600.00 K
MRTX annual cost of goods sold is $600.00 thousand

Annual Interest Expense

-
MRTX annual interest expense value is unknown

Quarterly SGA

$72.00 M
-$3.49 M-4.62%

September 30, 2023

Summary

Performance

3-Month Change

-4.62%

1-Year Change

+18.43%

3-Year Change

+255.58%

5-Year Change

+1255.19%

MRTX Quarterly SGA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

High & Low

All-time High

$75.49 M
MRTX quarterly SGA is currently -4.62% below its historical high of $75.49 million

3-Year Low

$43.53 M
MRTX quarterly SGA is currently +65.39% above its 3-year low

Earnings dates

Last Quarterly Earnings Report Date

Sep 30, 2023
MRTX previous earnings announcement was published on Sep 30, 2023

Next Quarterly Earnings Report Date

N/A
MRTX next earnings announcement has not yet been scheduled

OtherMRTXexpensesmetrics:

Quarterly Total Expenses

$188.45 M
MRTX quarterly total expenses is $188.45 million

Quarterly Operating Expenses

$186.77 M
MRTX quarterly total operating expenses is $186.77 million

Quarterly Cost Of Goods Sold

$1.69 M
MRTX quarterly cost of goods sold is $1.69 million

Quarterly Interest Expense

-
MRTX quarterly interest expense value is unknown

TTM SGA

-$10.88 B
-$725.88 M-7.15%

September 30, 2023

Summary

Performance

3-Month Change

-3977.79%

1-Year Change

-5220.2%

3-Year Change

-15576.47%

5-Year Change

-25657.96%

MRTX TTM SGA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

High & Low

All-time High

-$32.40 M

3-Year Low

-$10.88 B
MRTX TTM SGA is currently at its 3-year low

Earnings dates

Last Quarterly Earnings Report Date

Sep 30, 2023
MRTX previous earnings announcement was published on Sep 30, 2023

Next Quarterly Earnings Report Date

N/A
MRTX next earnings announcement has not yet been scheduled

OtherMRTXexpensesmetrics:

Annual Total Expenses

$772.02 M
MRTX annual total expenses is $772.02 million

Annual Operating Expenses

$771.42 M
MRTX annual total operating expenses is $771.42 million

TTM Cost Of Goods Sold

$4.39 M
MRTX TTM cost of goods sold is $4.39 million

TTM Interest Expense

-
MRTX TTM interest expense value is unknown

Selling, General & Administrative Expenses Formula

SGA = Total Operating Expenses - Cost of Goods Sold - Research & Development

Annual SGA

$239.80 M
MRTX annual SGA is $239.80 million

Annual Operating Expenses

$771.42 M
MRTX annual total operating expenses is $771.42 million

Annual Cost Of Goods Sold

$600.00 K
MRTX annual cost of goods sold is $600.00 thousand

MRTX Selling, General & Administrative Expenses Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year+75.5%+18.4%-5220.2%
3 y3 years+463.3%+255.6%-10000.0%
5 y5 years+1682.9%+1255.2%-10000.0%

MRTX Selling, General & Administrative Expenses Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-yearat high-43.0%-4.6%-39.5%+83.7%at low
5 y5-yearat high-82.2%-4.6%-83.0%+300.4%at low
alltimeall timeat high-98.9%-4.6%-99.4%>+9999.0%at low

Mirati Therapeutics Selling, General & Administrative Expenses History

DateAnnualQuarterlyTTM
Sep 2023
-
$72.00 M(-4.6%)
$291.80 M(+4.0%)
Jun 2023
-
$75.49 M(+2.7%)
$280.60 M(+8.2%)
Mar 2023
-
$73.49 M(+3.8%)
$259.34 M(+8.1%)
Dec 2022
$239.80 M(+75.4%)
$70.82 M(+16.5%)
$239.80 M(+12.8%)
Sep 2022
-
$60.80 M(+12.1%)
$212.51 M(+13.7%)
Jun 2022
-
$54.23 M(+0.5%)
$186.90 M(+15.2%)
Mar 2022
-
$53.95 M(+23.9%)
$162.28 M(+18.7%)
Dec 2021
$136.68 M(+63.9%)
$43.53 M(+23.7%)
$136.68 M(+15.4%)
Sep 2021
-
$35.18 M(+18.8%)
$118.48 M(+14.4%)
Jun 2021
-
$29.61 M(+4.4%)
$103.55 M(+10.5%)
Mar 2021
-
$28.35 M(+11.9%)
$93.72 M(+12.4%)
Dec 2020
$83.41 M(+95.9%)
$25.34 M(+25.1%)
$83.41 M(+18.6%)
Sep 2020
-
$20.25 M(+2.4%)
$70.31 M(+15.7%)
Jun 2020
-
$19.78 M(+9.6%)
$60.74 M(+19.4%)
Mar 2020
-
$18.05 M(+47.5%)
$50.86 M(+19.5%)
Dec 2019
$42.57 M(+96.4%)
$12.23 M(+14.5%)
$42.57 M(+16.0%)
Sep 2019
-
$10.69 M(+8.0%)
$36.71 M(+17.1%)
Jun 2019
-
$9.89 M(+1.4%)
$31.34 M(+19.2%)
Mar 2019
-
$9.76 M(+53.2%)
$26.29 M(+21.3%)
Dec 2018
$21.68 M(+61.2%)
$6.37 M(+20.0%)
$21.68 M(+18.5%)
Sep 2018
-
$5.31 M(+9.8%)
$18.29 M(+13.6%)
Jun 2018
-
$4.84 M(-6.1%)
$16.10 M(+8.0%)
Mar 2018
-
$5.15 M(+72.7%)
$14.91 M(+10.9%)
Dec 2017
$13.45 M(-12.0%)
$2.98 M(-4.3%)
$13.45 M(-6.4%)
Sep 2017
-
$3.12 M(-14.6%)
$14.37 M(-2.4%)
Jun 2017
-
$3.65 M(-1.1%)
$14.72 M(-0.9%)
Mar 2017
-
$3.69 M(-5.3%)
$14.86 M(-2.9%)
Dec 2016
$15.29 M(-2.9%)
$3.90 M(+12.3%)
$15.29 M(+2.2%)
Sep 2016
-
$3.48 M(-8.2%)
$14.97 M(-4.4%)
Jun 2016
-
$3.79 M(-8.3%)
$15.65 M(-2.8%)
Mar 2016
-
$4.13 M(+15.5%)
$16.11 M(+2.2%)
Dec 2015
$15.76 M(+24.1%)
$3.58 M(-14.1%)
$15.76 M(+1.3%)
Sep 2015
-
$4.16 M(-1.9%)
$15.55 M(+3.3%)
Jun 2015
-
$4.24 M(+12.2%)
$15.05 M(+9.1%)
Mar 2015
-
$3.78 M(+12.3%)
$13.79 M(+8.6%)
Dec 2014
$12.70 M
$3.37 M(-8.1%)
$12.70 M(+6.9%)
Sep 2014
-
$3.66 M(+22.6%)
$11.87 M(-0.5%)
Jun 2014
-
$2.99 M(+11.2%)
$11.93 M(+5.3%)
DateAnnualQuarterlyTTM
Mar 2014
-
$2.69 M(+5.7%)
$11.32 M(+1.4%)
Dec 2013
$11.18 M(+106.3%)
$2.54 M(-31.6%)
$11.16 M(+11.4%)
Sep 2013
-
$3.72 M(+56.0%)
$10.02 M(+24.9%)
Jun 2013
-
$2.38 M(-5.6%)
$8.02 M(+19.3%)
Mar 2013
-
$2.52 M(+80.5%)
$6.72 M(+24.1%)
Dec 2012
$5.42 M(+29.0%)
$1.40 M(-18.6%)
$5.42 M(+3.3%)
Sep 2012
-
$1.72 M(+58.7%)
$5.24 M(+14.2%)
Jun 2012
-
$1.08 M(-11.3%)
$4.59 M(-0.3%)
Mar 2012
-
$1.22 M(-0.4%)
$4.61 M(+3.7%)
Dec 2011
$4.20 M(-31.4%)
$1.23 M(+15.0%)
$4.44 M(+4.4%)
Sep 2011
-
$1.06 M(-3.0%)
$4.26 M(-27.0%)
Jun 2011
-
$1.10 M(+4.1%)
$5.83 M(-1.0%)
Mar 2011
-
$1.05 M(+1.4%)
$5.89 M(-3.6%)
Dec 2010
$6.12 M(+20.7%)
$1.04 M(-60.6%)
$6.11 M(-9.5%)
Sep 2010
-
$2.64 M(+128.4%)
$6.76 M(+27.1%)
Jun 2010
-
$1.16 M(-9.2%)
$5.31 M(+6.1%)
Mar 2010
-
$1.27 M(-24.4%)
$5.01 M(+4.6%)
Dec 2009
$5.07 M(-2.7%)
$1.68 M(+40.3%)
$4.79 M(+34.5%)
Sep 2009
-
$1.20 M(+41.2%)
$3.56 M(-5.1%)
Jun 2009
-
$850.20 K(-19.1%)
$3.75 M(-21.0%)
Mar 2009
-
$1.05 M(+130.5%)
$4.75 M(-10.9%)
Dec 2008
$5.21 M(+5.1%)
$456.00 K(-67.2%)
$5.33 M(-13.4%)
Sep 2008
-
$1.39 M(-24.8%)
$6.15 M(+3.2%)
Jun 2008
-
$1.85 M(+13.2%)
$5.96 M(+12.2%)
Mar 2008
-
$1.63 M(+27.6%)
$5.31 M(+12.9%)
Dec 2007
$4.96 M(+15.9%)
$1.28 M(+6.8%)
$4.70 M(+7.5%)
Sep 2007
-
$1.20 M(-0.2%)
$4.37 M(+3.8%)
Jun 2007
-
$1.20 M(+17.0%)
$4.22 M(+4.5%)
Mar 2007
-
$1.03 M(+8.0%)
$4.03 M(-4.5%)
Dec 2006
$4.28 M(+1.8%)
$950.20 K(-8.6%)
$4.22 M(-4.5%)
Sep 2006
-
$1.04 M(+2.1%)
$4.42 M(+2.2%)
Jun 2006
-
$1.02 M(-16.3%)
$4.33 M(-1.3%)
Mar 2006
-
$1.22 M(+6.0%)
$4.38 M(+6.8%)
Dec 2005
$4.20 M(+8.6%)
$1.15 M(+21.6%)
$4.10 M(+38.8%)
Sep 2005
-
$944.20 K(-12.2%)
$2.96 M(+46.9%)
Jun 2005
-
$1.08 M(+14.8%)
$2.01 M(+114.8%)
Mar 2005
-
$936.80 K
$936.80 K
Dec 2004
$3.87 M(+41.1%)
-
-
Dec 2003
$2.74 M
-
-

FAQ

  • What is Mirati Therapeutics annual SGA?
  • What is the all time high annual SGA for Mirati Therapeutics?
  • What is Mirati Therapeutics annual SGA year-on-year change?
  • What is Mirati Therapeutics quarterly SGA?
  • What is the all time high quarterly SGA for Mirati Therapeutics?
  • What is Mirati Therapeutics quarterly SGA year-on-year change?
  • What is Mirati Therapeutics TTM SGA?
  • What is the all time high TTM SGA for Mirati Therapeutics?
  • What is Mirati Therapeutics TTM SGA year-on-year change?

What is Mirati Therapeutics annual SGA?

The current annual SGA of MRTX is $239.80 M

What is the all time high annual SGA for Mirati Therapeutics?

Mirati Therapeutics all-time high annual SGA is $239.80 M

What is Mirati Therapeutics annual SGA year-on-year change?

Over the past year, MRTX annual SGA has changed by +$103.12 M (+75.45%)

What is Mirati Therapeutics quarterly SGA?

The current quarterly SGA of MRTX is $72.00 M

What is the all time high quarterly SGA for Mirati Therapeutics?

Mirati Therapeutics all-time high quarterly SGA is $75.49 M

What is Mirati Therapeutics quarterly SGA year-on-year change?

Over the past year, MRTX quarterly SGA has changed by +$11.20 M (+18.43%)

What is Mirati Therapeutics TTM SGA?

The current TTM SGA of MRTX is -$10.88 B

What is the all time high TTM SGA for Mirati Therapeutics?

Mirati Therapeutics all-time high TTM SGA is -$32.40 M

What is Mirati Therapeutics TTM SGA year-on-year change?

Over the past year, MRTX TTM SGA has changed by -$11.09 B (-5220.20%)